Welcome to our dedicated page for Iveric Bio news (Ticker: ISEE), a resource for investors and traders seeking the latest updates and insights on Iveric Bio stock.
Iveric Bio (NASDAQ: ISEE), now a subsidiary of Astellas Pharma, remains a leader in developing innovative therapies for retinal diseases including age-related macular degeneration. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic developments following the company's acquisition.
Access timely updates on Avacincaptad Pegol and other pipeline candidates targeting Geographic Atrophy. Our curated news collection features official press releases, trial result analyses, and partnership announcements from trusted sources. Track progress in ophthalmology research through verified updates on therapeutic advancements and regulatory pathways.
Key content includes updates on late-stage clinical programs, manufacturing developments, and scientific collaborations. All information is vetted for accuracy and relevance to investor decision-making. Bookmark this page for streamlined access to critical updates about Iveric Bio's contributions to retinal disease treatment under Astellas' global infrastructure.
IVERIC bio, Inc. (Nasdaq: ISEE) reported its fourth-quarter and full-year results for 2020, showcasing progress in its GATHER2 clinical trial for Zimura®, aimed at treating geographic atrophy (GA) related to age-related macular degeneration (AMD). Enrollment for GATHER2 is ahead of schedule, with completion expected by Q3 2021. Financially, the company faced a net loss of $25.4 million for Q4 2020, totaling $84.5 million for the year. Despite increased R&D expenses, IVERIC bio maintains sufficient cash reserves to support operations into 2024.
On March 1, 2021, Iveric Bio (Nasdaq: ISEE) granted non-statutory stock options to purchase 41,500 shares to two new non-executive employees as part of the 2019 Inducement Stock Incentive Plan. The options have an exercise price of $6.49 per share, equating to the company's closing stock price on the grant date. Vesting occurs over four years, starting with 25% on March 1, 2022, and continuing monthly thereafter, contingent upon the employees' ongoing service. This grant aims to enhance recruitment efforts for the company, which focuses on treating retinal diseases.
IVERIC bio (Nasdaq: ISEE) announced that CEO Glenn P. Sblendorio and Chief Strategy Officer Pravin U. Dugel, M.D., will engage in a fireside chat at the Cowen 41st Annual Health Care Conference on March 4 at 9:50 a.m. ET. Investors and the public can access a live webcast on the Iveric Bio website and an archived replay will be available for two weeks post-conference. Iveric Bio focuses on innovative treatments for retinal diseases, aiming to address significant unmet medical needs.
IVERIC bio, Inc. (Nasdaq: ISEE) will announce its fourth quarter and full year 2020 financial results on March 3, 2021. Following the release, the management team will host a live conference call at 8:00 a.m. ET to discuss the financial outcomes and general business updates. Investors can access the call by dialing 888-221-3881 (USA) or 323-794-2590 (International) with passcode 9597743. The call will also be available via webcast on the IVERIC bio website.
The company focuses on developing treatments for retinal diseases, highlighting its commitment to addressing significant unmet medical needs.
IVERIC bio, Inc. (Nasdaq: ISEE) granted non-statutory stock options to purchase 28,000 shares to two new non-executive employees on January 4, 2021. This issuance, part of the 2019 Inducement Stock Incentive Plan, serves as a material incentive for the employees' acceptance of their roles. The options have an exercise price of $6.895 per share, mirroring the company's closing share price on that date. Each option vests over four years, contingent upon continued employment.
IVERIC bio focuses on developing innovative treatments for retinal diseases.
IVERIC bio, Inc. (Nasdaq: ISEE) will have CEO Glenn P. Sblendorio present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 2:50 p.m. Eastern Time via a virtual session. Investors and the public can access the live webcast on IVERIC bio's website, with a replay available for two weeks post-conference. The company focuses on developing innovative treatments for retinal diseases, emphasizing their commitment to finding solutions for conditions with significant unmet medical needs.
IVERIC bio, Inc. (NASDAQ: ISEE) announced the grant of equity-based awards to a newly hired employee as part of its 2019 Inducement Stock Incentive Plan. The compensation committee approved the stock option to purchase 34,000 shares at an exercise price of $6.37 per share, with a ten-year term and vesting over four years. An additional grant of 7,000 restricted stock units will vest fully on December 3, 2021. These grants are designed to incentivize employee retention and align with the company's mission to develop treatments for retinal diseases.
IVERIC bio reported financial results for Q3 2020, highlighting significant progress in its clinical programs for Zimura, a treatment for geographic atrophy related to age-related macular degeneration (AMD). The Company achieved positive results from the GATHER1 Phase 3 trial and initiated GATHER2 enrollment. As of September 30, 2020, cash and equivalents totaled $231.1 million, projected to last through mid-2024. R&D expenses rose to $18.8 million, contributing to a net loss of $25.5 million for the quarter.
IVERIC bio (Nasdaq: ISEE) announced its participation in several upcoming virtual investor conferences in November 2020. Key events include the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10, and the Stifel 2020 Virtual Healthcare Conference on November 16, where Dr. Pravin U. Dugel will present an overview of the company. Additionally, IVERIC will participate in the Eyecelerator 2020 Virtual Conference on October 30 and November 6, discussing retinal diseases and treatment options. Webcasts will be available on the company's website.
IVERIC bio announced it will report its third quarter 2020 financial results on November 2, 2020. A live conference call will follow at 8:00 a.m. Eastern Time to discuss the financial outcomes and provide a business update. Participants can join via phone or listen to the webcast on the company's website. IVERIC bio focuses on developing novel treatments for retinal diseases, including therapeutic and gene therapy candidates for age-related and inherited diseases. Additional information can be found on their website.
